RT Journal Article
SR Electronic
T1 Deep learning driven quantification of interstitial fibrosis in kidney biopsies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.03.21249179
DO 10.1101/2021.01.03.21249179
A1 Zheng, Yi
A1 Cassol, Clarissa A.
A1 Jung, Saemi
A1 Veerapaneni, Divya
A1 Chitalia, Vipul C.
A1 Ren, Kevin
A1 Bellur, Shubha S.
A1 Boor, Peter
A1 Barisoni, Laura M.
A1 Waikar, Sushrut S.
A1 Betke, Margrit
A1 Kolachalama, Vijaya B.
YR 2021
UL http://medrxiv.org/content/early/2021/01/04/2021.01.03.21249179.abstract
AB Interstitial fibrosis and tubular atrophy (IFTA) on a renal biopsy are strong indicators of disease chronicity and prognosis. Techniques that are typically used for IFTA grading remain manual, leading to variability among pathologists. Accurate IFTA estimation using computational techniques can reduce this variability and provide quantitative assessment by capturing the pathologic features. Using trichrome-stained whole slide images (WSIs) processed from human renal biopsies, we developed a deep learning (DL) framework that captured finer pathological structures at high resolution and overall context at the WSI-level to predict IFTA grade. WSIs (n=67) were obtained from The Ohio State University Wexner Medical Center (OSUWMC). Five nephropathologists independently reviewed them and provided fibrosis scores that were converted to IFTA grades: <=10% (None or minimal), 11-25% (Mild), 26-50% (Moderate), and >50% (Severe). The model was developed by associating the WSIs with the IFTA grade determined by majority voting (reference estimate). Model performance was evaluated on WSIs (n=28) obtained from the Kidney Precision Medicine Project (KPMP). There was good agreement on the IFTA grading between the pathologists and the reference estimate (Kappa=0.622±0.071). The accuracy of the DL model was 71.8±5.3% on OSUWMC and 65.0±4.2% on KPMP datasets, respectively. Identification of salient image regions by combining microscopic and WSI-level pathological features yielded visual representations that were consistent with the pathologist-based IFTA grading. Our approach to analyzing microscopic- and WSI-level changes in renal biopsies attempts to mimic the pathologist and provides a regional and contextual estimation of IFTA. Such methods can assist clinicopathologic diagnosis.Translational statement Pathologists rely on interstitial fibrosis and tubular atrophy (IFTA) to indicate chronicity in kidney biopsies and provide a prognostic indicator of renal survival. Although guidelines for evaluation of IFTA exist, there is variability in IFTA estimation among pathologists. In this work, digitized kidney biopsies were independently reviewed by five nephropathologists and majority voting on their ratings was used to determine the IFTA grade. Using this information, a deep learning model was developed that captured microscopic and holistic features on the digitized biopsies and accurately predicted the IFTA grade. The study illustrates that deep learning can be utilized effectively to perform IFTA grading, thus enhancing conventional clinicopathologic diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementVBK is supported by grants from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through BU-CTSI Grant (1UL1TR001430), a Scientist Development Grant (17SDG33670323) and a Strategically Focused Research Network (SFRN) Center Grant (20SFRN35460031) from the American Heart Association, and a Hariri Research Award from the Hariri Institute for Computing and Computational Science & Engineering at Boston University, and NIH grants (R01-AG062109 and R21-CA253498). VCC is supported by NIH grants (R21-DK119740 and R01-HL132325). PB is supported by the German Research Foundation (DFG; SFB/TRR57, SFB/TRR219, BO3755/3-1, BO3755/9-1, BO3755/13-1), the German Federal Ministries of Education and Research (BMBF: STOP-FSGS-01GM1901A), Health (DEEP LIVER, ZMVI1-2520DAT111) and Economic Affairs and Energy (EMPAIA). SSW is supported by NIH grants (R21-DK119751 and U01-DK085660). MB is supported by National Science Foundation grants (#1838193 and #1551572).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Renal biopsy as well as patient data collection, staining and digitization followed protocols approved by the Institutional Review Board at OSUWMC (Study number: 2018H0495)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the OSUWMC can be obtained upon request and subject to institutional approval. Data from KPMP can be freely downloaded from https://www.kpmp.org.